Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
OpenAI Restricts Astra AI Over Cyberattack Risks 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
NEWTON, Mass., March 06, 2018 -- Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Chris Schelling, CEO and Founder, will provide a corporate overview at the 30th Annual ROTH Conference, being held March 11-14, 2018 in California.
| Acer Therapeutics Conference Presentation Details | ||||||
| Date: | Tuesday, March 13 | |||||
| Time: | 1:30 pm Pacific Time (4:30 pm Eastern Time) | |||||
| Location: | The Ritz Carlton, Orange County, GREEN - SALON 3 | |||||
| Webcast: | https://acertx.com/investor-relations/events-presentations/ | |||||
About Acer Therapeutics
Acer, headquartered in Newton, MA, is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Acer’s late-stage clinical pipeline includes two candidates for severe genetic disorders for which there are few or no FDA-approved treatments: EDSIVO™ (celiprolol) for vascular Ehlers-Danlos syndrome (vEDS), and ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD). There are no FDA-approved drugs for vEDS and MSUD and limited options for UCD, which collectively impact more than 7,000 patients in the United States. Acer’s product candidates have clinical proof-of-concept and mechanistic differentiation, and Acer intends to seek approval for them in the U.S. by using the regulatory pathway established under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FFDCA, that allows an applicant to rely for approval at least in part on third-party data, which is expected to expedite the preparation, submission, and potential approval of a marketing application.
For more information, visit www.acertx.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-535-7743
[email protected]
